Allergies (Dec 2022)

<i>Bacillus subtilis</i> Provides Long-Term Protection in a Murine Model of Allergic Lung Disease by Influencing Bacterial Composition

  • Rosalinda Monroy Del Toro,
  • Ryan Incrocci,
  • Olivia Negris,
  • Shaina McGrath,
  • Julie A. Swartzendruber

DOI
https://doi.org/10.3390/allergies3010001
Journal volume & issue
Vol. 3, no. 1
pp. 1 – 10

Abstract

Read online

Probiotics are an attractive target for reducing the incidence of allergic disease. Bacillus subtilis is a gut-associated probiotic bacteria that can suppress allergic lung disease; however, it is not clear for how long this protection lasts. We exposed C57Bl/6 mice to B. subtilis via oral gavage and challenged them with intranasal house-dust mite for up to 8 weeks. We found that B. subtilis treatment was able to provide protection from eosinophil infiltration of the airways for 3 weeks. This loss of protection correlated with an increase in the eosinophil chemoattractant CCL24. Additionally, we demonstrate that B. subtilis treatment altered the bacterial composition by increasing the phylum Bacteroidetes and Verrucomicorbiota. The phylum Verrucomicorbiota was reduced in B. subtilis-treated mice at 8 weeks when protection was lost. These results support B. subtilis as a prophylactic for preventing the production of allergic lung disease and highlights that protection can last up to 3 weeks. This work also expands our understanding of how B. subtilis mediates protection and that in addition to modifying the immune system it is also altering the host microbiota.

Keywords